相关实验视频

Updated: Jun 20, 2025

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

A Parasite Rescue and Transformation Assay for Antileishmanial Screening Against Intracellular Leishmania donovani Amastigotes in THP1 Human Acute Monocytic Leukemia Cell Line

Published on: December 30, 2012

基于尿液的非侵入性ELISA测试使用重组Leishmania蛋白来诊断体Leishmaniasis

Raquel S B Câmara¹, Isabela A G Pereira¹, Daniela P Lage¹

¹Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, Minas Gerais, Brazil.

|July 19, 2024

概括

尿液分析显示,对诊断体莱什曼病 (TL) 是有前途的,为血液检测提供了一种不那么侵入性的替代方案. 这项研究发现,以尿为基础的检测方法,特别是使用rLiHyV抗原,实现了TL诊断的高灵敏度和特异性.

科学领域:

传染性疾病传染性疾病
寄生虫学的寄生虫学
生物标志物发现发现

背景情况:

目前对体莱什曼病 (TL) 的诊断方法存在灵敏度和特异性的变化.
血清分析对内脏莱什曼病 (VL) 有效,但对TL的表现不佳.
血清的血液采集是侵入性的,不舒服的,需要专门的基础设施和人员.

研究的目的:

评估尿液作为潜在的生物样本,用于诊断体莱什曼病 (TL).
评估尿液和血清中不同莱什曼尼亚抗原 (rLiHyV,Peptide1,Peptide2,SLA) 的诊断性能.

主要方法:

从患者中收集了215个配对的尿液和血清样本.
作为抗原使用了一种Leishmania蛋白 (rLiHyV),两种衍生B细胞表位 (Peptide1,Peptide2) 和一种Leishmania抗原提取物 (SLA).
在尿液和血清样本中分析了抗原检测的灵敏度和特异性.

主要成果:

在血清中,rLiHyV显示了TL诊断的85%灵敏度和97.5%特异性.
在尿液中,rLiHyV表现出优异的性能,具有95%的灵敏度和100%的特异性.
使用rLiHyV的尿基检测在敏感性方面显著超过了其他抗原和基于血清的方法.

结论:

初步发现表明,尿液是TL检测可行的替代生物样本.
rLiHyV抗原显示出开发改进的,非侵入性的TL诊断测试的巨大潜力.
需要进一步的研究来验证尿液作为体莱什曼病的主要诊断液.

关键词:

诊断诊断诊断诊断诊断再组合蛋白质是一种重组蛋白质.血清的血清是什么意思合成的合成.体莱什曼病 - 体莱什曼病尿液尿液尿液

更多相关视频

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

Production and Optimization of LTE, a Leishmania tarentolae Derived Cell-Free Protein Expression System for Recombinant Protein Production

Production and Optimization of LTE, a Leishmania tarentolae Derived Cell-Free Protein Expression System for Recombinant Protein Production

Published on: November 8, 2024

相关概念视频

Enzyme-Linked Immunosorbent Assay

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or...